AR059802A1 - Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp. - Google Patents

Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp.

Info

Publication number
AR059802A1
AR059802A1 ARP070100979A ARP070100979A AR059802A1 AR 059802 A1 AR059802 A1 AR 059802A1 AR P070100979 A ARP070100979 A AR P070100979A AR P070100979 A ARP070100979 A AR P070100979A AR 059802 A1 AR059802 A1 AR 059802A1
Authority
AR
Argentina
Prior art keywords
alkyl
groups
halo
cyano
optionally substituted
Prior art date
Application number
ARP070100979A
Other languages
English (en)
Inventor
Ravi Shanker Garigipati
Bruce Allen Lefker
David Austen Perry
George Chang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR059802A1 publication Critical patent/AR059802A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Compuestos de dibencilamina y derivados, composiciones farmacéuticas que contienen estos compuestos y el uso de estos compuestos para elevar los niveles plasmáticos de ciertos Iípidos, incluyendo el colesterol asociado a lipoproteínas de alta densidad y para reducir los niveles plasmáticos de otros lípidos, tales como el colesterol LDL y los triglicéridos y, por consiguiente, para tratar enfermedades que se exacerban por bajos niveles de colesterol-HDL y/o altos niveles de colesterol-LDL y triglicéridos, tales como aterosclerosis y enfermedades cardiovasculares en algunos mamíferos, incluyendo seres humanos. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable de dicho compuesto; donde A es - COOalquilo C1-4, ciano, -CHO, -CONH2, -COalquilo C1-4 o Q, donde Q es un anillo de cinco o seis miembros, totalmente saturado, parcialmente insaturado o totalmente insaturado, donde cada átomo del anillo, excepto para el átomo conectado al N de la formula 1, puede reemplazarse por un átomo de nitrogeno, oxigeno o azufre, y donde cada átomo del anillo puede estar opcionalmente sustituido con ciano, una cadena lineal o ramificada, totalmente saturada, parcialmente insaturada o tota mente insaturada, que tiene de 1 a 6 átomos de carbono, o un anillo totalmente saturado, parcialmente insaturado o totalmente insaturado, que tiene de 3 a 8 átomos de carbono, donde cada átomo de carbono de dicha cadena o de dicho anillo se reemplaza opcionalmente por un heteroátomo seleccionado entre nitrogeno, oxigeno y azufre, y dicho átomo de carbono de dicha cadena o de dicho anillo está opcionalmente mono-, di- o trisustituido con amino, halo, ciano, hidroxi, oxo, carboxilo, alcoxicarbonilo C1-6, (alquilo C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo, (alcoxi C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo) o (alquiltio C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo), y dicho átomo de nitrogeno de dicha cadena o de dicho anillo está opcionalmente mono- o disustituido con ciano, oxo, alcoxicarbonilo C1-6 o (alquilo C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo), dicho átomo de azufre de dicha cadena o de dicho anillo está sustituido con uno o dos grupos oxo, uno a cinco grupos fluor o amino, y dicha cadena o dicho anillo está opcionalmente mono- di- o trisustituido con un grupo V, donde V es un anillo de tres a seis miembros, totalmente saturado, parcialmente saturado o totalmente insaturado, que contiene de cero a cuatro heteroátomos seleccionados entre nitrogeno, oxigeno o azufre y opcionalmente sustituido con uno a cinco grupos seleccionados entre hidrogeno, halo, ciano, hidroxi, oxo, carboxilo, alcoxicarbonilo C1-6, (alquilo C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo), (alcoxi C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo) o (alquiltio C1-6 opcionalmente sustituido con uno a nueve grupos halo o uno o dos grupos hidroxilo); B es -NR15R16 o un heterociclo de 3 a 8 miembros que tiene 1 o 2 heteroátomos seleccionados entre oxigeno, nitrogeno y azufre, donde dicho heterociclo está unido a Y en un heteroátomo y donde dicho heterociclo está opcionalmente mono- o di-sustituido con R20, X es C o N, donde si X es N, R4 está ausente; Y es - CR11R12, cada uno de R1, R2, R3, R4, R5, R6 y R7 es independientemente hidrogeno, halo, ciano, hidroxi, nitro, (alquilo C1-6 opcionalmente sustituido con uno a nueve grupos halo, uno o dos grupos hidroxilo, uno o dos alcoxi C1-6, uno o dos grupos amino, uno o dos grupos nitro, ciano, oxo o carboxi), (alcoxi C1-6 opcionalmente sustituido con uno a nueve grupos halo, uno o dos grupos hidroxilo o ciano) o (alquiltio C1-6 opcionalmente sustituido con uno a nueve grupos halo, uno o dos grupos hidroxilo o ciano), o R1 y R2 o R2 y R3 se toman juntos para formar un anillo de 5 a 7 miembros, parcialmente insaturado o totalmente insaturado, donde cada átomo de carbono de dicho anillo se reemplaza opcionalmente por un átomo de oxigeno, donde los átomos de oxigeno no están conectados entre si, donde dicho anillo está opcionalmente mono-, di-, tri- o tetra-sustituido con halo, y opcionalmente mono- o di-sustituido con hidroxi, amino, nitro, ciano, oxo, carboxi, (alquilo C1-6 opcionalmente sustituido con uno a nueve grupos halo, uno o dos grupos hidroxilo, uno o dos grupos alcoxi C1-6, uno o dos grupos amino, uno o dos grupos nitro, ciano, oxo o carboxi) o (alcoxi C1-6 opcionalmente sustituido con uno a nueve grupos halo, uno o dos grupos hidroxilo o ciano); cada R8, R9, R10, R13 y R14 es independientemente hidrogeno, arilo o alquilo C1-6 opcionalmente sustituido con uno a nueve grupos halo; R11 es hidrogeno, arilo, (cicloalquilo C3-6 opcionalmente sustituido con arilo, uno a tres grupos alquilo C1-6, uno a tres grupos alcoxi C1-6, uno a tres grupos haloalquilo C1-6, uno a tres grupos haloalcoxi C1-6, uno o dos grupos hidroxilo o uno a nueve grupos halo) o (alquilo C1-6 donde dicho grupo alquilo C1-6 está opcionalmente sustituido con arilo, uno a tres grupos alcoxi C1-6, uno a tres grupos haloalquilo C1-6, uno a tres grupos haloalcoxi C1-6, uno o dos grupos hidroxilo o uno a nueve grupos halo); R12 es hidrogeno; cada uno de R15 y R16 es independientemente hidrogeno, -alquil C1-6-NR8R9, -alquil C0-6-CO-NR8R9, -alquil C0-6-CO-OR10, -alquil C1-6-NR13-alquil C0-6-CO-O-R10, -alquil C1-6-NR13-alquil C0-6-CO-R14, -alquil C1-6-NR13-alquil C0-6-SO2R10, -alquil C1-6-O-CO-NR8R9, -alquenil C2-6-CO-O-R10, -alquil C0-6-arilo, -alquil C0-6-heteroarilo, -alquil C1-6-O-arilo, -alquil C1-6-O-heteroarilo, -alquil C0-6-heterociclo, -alquil C0-6-cicloalquilo C3-6, -alquil C0-6-cicloalquenilo C3-6, alquinilo C2-6, alquenilo C2-6, alquilo C1-6, ciano o -CO-alquilo C1- 6, donde cada uno de dichos sustituyentes arilo, heteroarilo, heterociclo, cicloalquenilo, cicloalquilo, alquinilo, alquenilo y alquilo está opcionalmente sustituido independientemente con uno a nueve grupos halo, uno o dos grupos hidroxi, uno a tres grupos alquilo C1-6, uno a tres grupos haloalquilo C1-6, uno a tres grupos alcoxi C1-6, uno a tres grupos haloalcoxi C1-6, uno o dos grupos amino, uno o dos grupos nitro, ciano, oxo o carboxi; y cada R20 es independientemente -alquil C0-6- NR8R9, -alquil C0-6-CO-NR8R9, -alquil C0-6-CO-OR10, -alquil C0-6-NR13-alquil C0-6-CO-O-R10, -alquil C0-6-NR13-alquil C0-6-CO-R14, -alquil C0-6-NR13-alquil C0-6-SO2R10, -alquil C0-6-O-CO-NR8R9, -O-alquil C1-6-CO-OR10, halo, -alquenil C2-6-CO-O-R10, - alquil C0-6-arilo, -alquil C0-6-heteroarilo, -alquil C0-6-O-arilo, -alquil C0-6-O-heteroarilo, -alquil C0-6-heterociclo, -alquil C0-6-cicloalquilo C3-6, - alquil C0-6-cicloalquenilo C3-6, alquinilo C2-6, alquenilo C2-6, alquilo C1-6, alcoxi C1-6, oxo, ciano o -CO-alquilo C1-6, donde cada uno de dichos sustituyentes arilo, heteroarilo, heterociclo, cicloalquenilo, cicloalquilo, alquinilo, alquenilo y alquilo está opcionalmente sustituido independientemente con uno a nueve grupos halo, uno o dos grupos hidroxi, uno o dos grupos alquilo C1-6, uno o dos grupos haloalquilo C1-6, uno o dos alcoxi C1-6, uno o dos grupos haloalcoxi C1-6, uno o dos grupos amino, uno o dos grupos nitro, ciano, oxo o carboxi.
ARP070100979A 2006-03-10 2007-03-09 Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp. AR059802A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78148806P 2006-03-10 2006-03-10
US11/619,299 US8383660B2 (en) 2006-03-10 2007-01-03 Dibenzyl amine compounds and derivatives

Publications (1)

Publication Number Publication Date
AR059802A1 true AR059802A1 (es) 2008-04-30

Family

ID=38085975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100979A AR059802A1 (es) 2006-03-10 2007-03-09 Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp.

Country Status (23)

Country Link
US (1) US8383660B2 (es)
EP (1) EP1994015B1 (es)
JP (1) JP4959731B2 (es)
KR (1) KR101059274B1 (es)
AP (1) AP2008004603A0 (es)
AR (1) AR059802A1 (es)
AU (1) AU2007226260B2 (es)
BR (1) BRPI0708753A2 (es)
CA (2) CA2717242A1 (es)
CR (1) CR10265A (es)
DK (1) DK1994015T3 (es)
DO (1) DOP2007000044A (es)
ES (1) ES2410859T3 (es)
IL (1) IL193572A (es)
MA (1) MA30272B1 (es)
MX (1) MX2008011045A (es)
NL (1) NL2000527C2 (es)
NO (1) NO20083642L (es)
PE (1) PE20071022A1 (es)
RS (1) RS20080409A (es)
TW (1) TW200736235A (es)
UY (1) UY30197A1 (es)
WO (1) WO2007105049A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100009582A (ko) * 2007-05-10 2010-01-27 화이자 리미티드 아제티딘 유도체 및 프로스타글란딘 ｅ2 길항제로서 그의 용도
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
CN102241667B (zh) * 2010-05-14 2013-10-23 中国人民解放军军事医学科学院毒物药物研究所 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
US10428019B2 (en) * 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
AU2012282109B2 (en) 2011-07-08 2016-06-23 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
MX356830B (es) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Adyuvante de acido nucleico quiral.
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
CN103351354B (zh) * 2013-06-09 2015-08-12 西安近代化学研究所 1-甲基-5-氨基四唑合成方法
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
WO2017030367A1 (ko) * 2015-08-17 2017-02-23 인제대학교 산학협력단 신규한 이소나이트라민 화합물 및 이를 포함하는 대사성 질환 예방 또는 치료용 조성물
KR101799793B1 (ko) 2015-08-17 2017-11-21 인제대학교 산학협력단 신규한 이소나이트라민 화합물 및 이를 포함하는 대사성 질환 예방 또는 치료용 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2161938A (en) 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2970082A (en) 1958-10-07 1961-01-31 Walker Lab Inc Aluminum nicotinate compositions for hypercholesteremia
DE1518133B1 (de) 1961-10-05 1970-08-20 Farmaceutici Italia Verfahren zur Herstellung eines neuen hypotensiv wirkenden Hendekapeptids
US3228943A (en) 1962-06-11 1966-01-11 Lumilysergol derivatives
US3338899A (en) 1962-07-09 1967-08-29 Aron Samuel 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds
US3238215A (en) 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
NL127065C (es) 1964-04-22
FR1460571A (fr) 1965-06-10 1966-03-04 Innothera Lab Sa Composés thiényl acétiques et leur préparation
FR6087M (es) 1967-01-10 1968-06-04
US3511836A (en) 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
FR2003097A1 (en) 1968-03-02 1969-11-07 Takeda Chemical Industries Ltd Cpds. of general formula (I) A=CH or N Spasmolytics and peripheral vasodilators. Dose: 100-200 mg/d. (p.o). Z and X are OH or reactive
GB1218591A (en) 1968-04-03 1971-01-06 Delalande Sa Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation
CH507249A (de) 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
FR2092133B1 (es) 1970-05-06 1974-03-22 Orsymonde
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US4146643A (en) 1973-12-18 1979-03-27 Sandoz Ltd. Increasing vigilance or treating cerebral insufficiency with substituted vincamines
NL175059C (nl) 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
DE2733747C2 (de) 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
IT1094076B (it) 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
RO118715B1 (ro) 1994-10-27 2003-09-30 Janssen Pharmaceutica Nv Inhibitori ai sintezei apolipoproteinei-b
US5521186A (en) 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
WO1996040640A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
YU23499A (sh) 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
AU2002307839B2 (en) 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
JP2003221376A (ja) 2001-11-21 2003-08-05 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
SI1533292T1 (sl) 2002-08-30 2007-08-31 Japan Tobacco Inc Dibenzilaminska spojina in njena medicinska uporaba
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
EP1737811B1 (en) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Cetp inhibitors
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AR053784A1 (es) 2004-11-23 2007-05-23 Pfizer Prod Inc Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas.
KR101238525B1 (ko) * 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
JP2009513573A (ja) * 2005-09-30 2009-04-02 メルク エンド カムパニー インコーポレーテッド コレステリルエステル転送蛋白阻害剤
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
AU2007226260A1 (en) 2007-09-20
CA2645291A1 (en) 2007-09-20
NO20083642L (no) 2008-09-29
AU2007226260B2 (en) 2012-02-09
JP2009529573A (ja) 2009-08-20
IL193572A (en) 2013-02-28
TW200736235A (en) 2007-10-01
NL2000527C2 (nl) 2008-02-06
PE20071022A1 (es) 2007-10-06
DOP2007000044A (es) 2007-09-15
KR101059274B1 (ko) 2011-08-24
MA30272B1 (fr) 2009-03-02
CA2645291C (en) 2011-06-28
CA2717242A1 (en) 2007-09-20
WO2007105049A1 (en) 2007-09-20
DK1994015T3 (da) 2013-06-24
UY30197A1 (es) 2007-10-31
EP1994015B1 (en) 2013-04-24
RS20080409A (en) 2009-07-15
KR20080093156A (ko) 2008-10-20
US8383660B2 (en) 2013-02-26
AP2008004603A0 (en) 2008-10-31
ES2410859T3 (es) 2013-07-03
CR10265A (es) 2008-09-23
IL193572A0 (en) 2009-05-04
US20070213314A1 (en) 2007-09-13
NL2000527A1 (nl) 2007-09-11
JP4959731B2 (ja) 2012-06-27
EP1994015A1 (en) 2008-11-26
MX2008011045A (es) 2008-09-08
BRPI0708753A2 (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
AR059802A1 (es) Compuestos y derivados de dibencilamina, combinaciones y composiciones farmaceuticas que los comprenden y el uso de estos derivados en el tratamiento de enfermedades mediadas por la actividad de cetp.
AR109789A2 (es) Compuestos lipídicos
AR123048A2 (es) Moduladores de p2x7
AR079455A1 (es) Composiciones para el crecimiento y/o recrecimiento del pelo
ES2649995T3 (es) Benzamidas
AR030523A1 (es) Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene.
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR094277A1 (es) Derivados de fumarato sustituidos con deuterio
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR094647A1 (es) Análogos de 7,8-morfinano cíclico
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
AR068639A1 (es) Derivados de biarilo
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR110443A1 (es) Inhibidores de histona metiltransferasas
BR112015012455A2 (pt) composto, e, uso de uma quantidade terapeuticamente efetiva de pelo menos um composto, ou um sal, solvato, éster ou pró-droga farmaceuticamente aceitáveis de um composto ou composição
AR044507A1 (es) Compuestos de quinolina y quinoxalina
UY31950A (es) Inhibidores de ciclopropil-polimerasa
AR087868A1 (es) Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met
DOP2013000191A (es) Derivados de heteroarilo como modulares de nachr alfa 7
AR089944A1 (es) Derivados de tetrahidro-quinazolinona

Legal Events

Date Code Title Description
FB Suspension of granting procedure